FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 267 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... September 9, 2025 Get to Know CaringBridge June 3, 2021 Reducing Health Care Disparities Through Cancer Clinical Trials November 30, 2020 Body Location May Influence Fate of Cells with Cancer-Causing Mutations April 29, 2022 Load more HOT NEWS Dogs Can Sniff Out COVID-19 After Just One Week Of Training,... Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... Immune cell count could determine whether chemotherapy is required in oropharyngeal...
